



Noxopharm's Sofra assets to be presented at global conference

Highlights

- Project with Australian biotechnology leader
- Delivery of self-amplifying mRNA vaccines
- Demonstrates Sofra™ versatility and industry interest

Sydney, 20 May 2026: Noxopharm Limited (ASX:NOX) is pleased to announce that data from a project involving Noxopharm's assets will be highlighted at an upcoming international conference.

The data will be presented by CSL, a global biopharma company, at the [Options for the Control of Influenza XIII Conference](#) in late August in Washington DC, and relates to how Noxopharm's novel oligonucleotides from its [Sofra™](#) technology platform could be used to improve the delivery of self-amplifying mRNA vaccines.

Developed from a [breakthrough discovery](#) in the immune system, Sofra comprises a novel class of drugs designed to precisely regulate innate immune signalling, targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines. It has potential applications across a wide range of immune-related conditions such as rheumatoid arthritis, lupus and diabetes, as well as oncology and off-target effects of RNA therapeutics.

The Options conference is the largest global scientific meeting focused on influenza prevention, control and treatment. It brings together the world's leading experts in virology, clinical care, public health and vaccine research to share the latest evidence, foster collaboration, and advance the global response to influenza.

Noxopharm CEO Dr Olivier Laczka said: "The Sofra platform could be used in many areas where inflammation plays a role, and we have made significant progress bringing it to a point where it is attracting attention not only because of its versatility, but also because of the breakthrough understanding of the immune system on which it is based."

-ENDS-

About the Sofra technology platform

Developed from a [breakthrough discovery](#) in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

[Sofra technology](#) has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: +61 425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

Shawn van Boheemen

T: +61 414 903 376

E: shawn.vanboheemen@noxopharm.com

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.